Coen van Hasselt
Professor Pharmacology
- Name
- Prof. dr. J.G.C. van Hasselt
- Telephone
- 071 5273266
- coen.vanhasselt@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-1664-7314
Coen van Hasselt is professor and head of the Division of Systems Pharmacology & Pharmacy at the Leiden Academic Centre for Drug Research (LACDR), Leiden University. He is leading the Quantitative Pharmacology group, which focuses on developing and applying quantitative pharmacological modeling approaches (pharmacometrics & systems-based modeling) to optimize translational drug development and to support individualized drug treatment, with a primary focus on antimicrobial agents and resistance. The group has strong computational expertise and in addition expertise in experimental models and assays for translational antimicrobial PK/PD. Other therapeutic areas of interest are anti-cancer drug pharmacology, adverse drug reactions and developing pharmacometric methodologies. In our work we collaborate extensively with both clinicians and several experimental groups. Coen received a PhD degree (2014) from the Netherlands Cancer Institute/Utrecht University, with a PhD thesis on novel integrative quantitative pharmacological modeling approaches to optimize drug treatment in oncology. He then was a postdoctoral researcher at the LACDR focusing on antibiotics PK/PD (2013-2015) and a postdoctoral research fellow (2015-2017) at the Ravi Iyengar lab focusing on innovative systems pharmacology approaches, at the Icahn School of Mount Sinai, NY, USA, supported by a competitive personal Marie Curie Individual Fellowship.
More information about Coen van Hasselt
PhD Candidates
News
-
From molecule to model: working together on better antibiotics -
Smart combinations of antibiotics can slow down resistance -
Finally solved: how the body's own marijuana spreads through the brain -
One million euros grant for smart antibiotic combinations – tackling resistant infections and antimicrobial resistance -
A new perspective on pneumonia: what does our body tell us about the cause? -
During the next pandemic, this mathematical model will speed up the search for treatment -
Powerful new Leiden 'super antibiotic' may overcome resistance -
Improving nature’s antibiotic -
Reliable research with virtual patients -
Dutch Research Council Open Science Fund grants for five Leiden projects -
New treatments for life-threatening disease sepsis -
Children become bacteria to learn about antibiotics -
Researchers tackle antibiotic-resistant bacteria -
Combating antibiotic resistance together -
Leiden researchers join forces against tuberculosis
-
Improving the treatment of newborn babies with life-threatening sepsis -
Master projects continue thanks to lab automation -
Two times KNMP Student Award for Leiden students -
International media report on Leiden dosage app for corona patients -
App helps doctors find the right dose of corona medication -
A headset and ample amounts of coffee: working from home in times of Corona -
Vote for the Discoverer of the Year -
Innovative approach to antibiotic resistance -
ZonMW awards funding for LACDR research project to develop novel biomarkers for bacterial infections
Postdoc
Former PhD Candidates
Coen van Hasselt is professor and head of the Division of Systems Pharmacology & Pharmacy at the Leiden Academic Centre for Drug Research (LACDR), Leiden University. He is leading the Quantitative Pharmacology group, which focuses on developing and applying quantitative pharmacological modeling approaches (pharmacometrics & systems-based modeling) to optimize translational drug development and to support individualized drug treatment, with a primary focus on antimicrobial agents and resistance. The group has strong computational expertise and in addition expertise in experimental models and assays for translational antimicrobial PK/PD. Other therapeutic areas of interest are anti-cancer drug pharmacology, adverse drug reactions and developing pharmacometric methodologies. In our work we collaborate extensively with both clinicians and several experimental groups.
Coen received a PhD degree (2014) from the Netherlands Cancer Institute/Utrecht University, with a PhD thesis on novel integrative quantitative pharmacological modeling approaches to optimize drug treatment in oncology. He then was a postdoctoral researcher at the LACDR focusing on antibiotics PK/PD (2013-2015) and a postdoctoral research fellow (2015-2017) at the Ravi Iyengar lab focusing on innovative systems pharmacology approaches, at the Icahn School of Mount Sinai, NY, USA, supported by a competitive personal Marie Curie Individual Fellowship.
Professor Pharmacology
- LACDR
- Divisie Systems Pharmacology and Pharmacy
- Aulin L.B.S., Lange D.W. de, Saleh M.A.A., Graaf P.H. van der, Völler S. & Hasselt J.G.C. (2021), Biomarker-guided individualization of antibiotic therapy, Clinical Pharmacology & Therapeutics 110(2): 346-360.
- Aulin L.B.S., Liakopoulos A., Graaf P.H. van der, Rozen D.E. & Hasselt J.G.C. (2021), Design principles of collateral sensitivity-based dosing strategies, Nature Communications 12: 5691.
- Aulin L.B.S., Koumans C.I.M., Haakman Y., Os W. van, Kraakman M.E.M., Gooskens J., Smits W.K., Liakopoulos A. & Hasselt J.G.C. van (2021), Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae, Journal of Antimicrobial Chemotherapy 76(2): 533-535.
- Zwep L.B., Duisters K.L.W., Jansen M., Guo T., Meulman J.J., Upadhyay P. & Hasselt J.G.C. (2021), Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling, CPT: Pharmacometrics and Systems Pharmacology 10(4): 350-361.
- Thomson K.M., Dyer C., Liu F., Sands K., Portal E., Carvalho M.J., Barrell M., Boostrom I., Dunachie S., Farzana R., Ferreira A., Frayne F., Hassan B., Jones E., Jones L., Mathias J., Milton R., Rees J., Chan G.J., Bekele D., Mahlet A., Basu S., Nandy R.K., Saha B., Iregbu K., Modibbo F., Uwaezuoke S., Zahra R., Shirazi H., Syed N.U., Mazarati J.B., Rucogoza A., Gaju L., Mehtar S., Bulabula A.N.H., Whitelaw A., Hasselt J.G.C. van & Walsh T.R. (2021), Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS), Lancet Infectious Diseases 21(12): 1677-1688.
- Tandar S.T., Clercq A. de, Aulin L.B.S., Biesen W. van, Delanghe S, Vanommeslaeghe F., Paepe P. de, Hasselt J.G.C. van Cock P.A. de & Eloot S. (2026), Model-based optimisation for teicoplanin dosing in patients undergoing maintenance haemodialysis, Clinical Microbiology and Infection 32(3): 466-473.
- Goldring C.E., Russomanno G., Pin C., Trairatphisan P., Beattie K.A., Fisher C.P., Piñero J., Brennan R.J., Clausznitzer D., Copple I.M., Kok T.M. de, Duckworth C.A., Furlong L.I., Füzi B., Gabor A., Gall L., Hengstler J., Hermjakob H., Hunter F., Jennen D., Koskinen M., Kunnen S.J., Lammens L., Lobentanzer S., Mohr M., Passini E., Pritchard D.M., Malik-Sheriff R.S., Rodríguez B., Rossman E.I., Saez-Rodríguez J., Schmidt F., Sison-Young R., Soininen I., Turner S., Water B. van de, Hasselt J.G.C. van, Venezia F., Willy J.A., Leishman D.J., Stevens J.L. & Laplanche L. (2026), Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety, Nature Reviews Drug Discovery 25: 138-153.
- Beldjenna M., Guedj J., Hasselt J.G.C. van & Guo T. (2026), Assessing the impact of bacterial heterogeneity on bacteriophage population dynamics, Journal of Pharmacokinetics and Pharmacodynamics 53(2): 15.
- Wang C., Wu Q., Liu X., Sudarsono L.M., Märtson A. & Hasselt J.G.C. van (2026), Experimental and virus-specific drivers of EC50 variability in antiviral assays evaluated using mathematical modeling, European Journal of Pharmaceutical Sciences 220: 107481.
- Wang Y., Bukkems L.H., Heine R. ter, Hasselt J.G.C. van, Koolen S.L.W., Hendikx J.J.M.A., Hulle T. van der, Kapiteijn E., Zwaveling J., Becker A., Heuvel M.M. van den, Theelen W.S.M.E., Oude Munnink T.H., Smit E.F., Guchelaar H.J. & Moes D.J.A.R. (2026), Model-based alternative dosing strategies for subcutaneous nivolumab to improve cost effectiveness, Clinical Pharmacokinetics 65: 621-632.
- Wang Y., Bukkems L.H., Heine R. ter, Hasselt J.G.C. van, Koolen S.L.W., Hendikx J.J.M.A., Hulle T. van der, Kapiteijn E., Zwaveling J., Becker A., Heuvel M.M. van den, Theelen W.S.M.E., Oude Munnink T.H., Smit E.F., Guchelaar H.J. & Moes D.J.A.R. (2026), Correction: model‑based alternative dosing strategies for subcutaneous nivolumab to improve cost effectiveness, Clinical Pharmacokinetics 65: 633-633.
- Otto M.E., Jacobs G.E., Mechelen J.C. van, Borghans L.G.J.M., Hasselt J.G.C. van & Aulin L.B.S. (2026), Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects: investigating metabolite contribution to subjective effects, British Journal of Clinical Pharmacology 92(7): 2260-2271.
- Mouraux A., Gousset S., Alvarez B., Baiula M., Bakker W., Bedini A., Bertayli M., Budda D., Carr R., Cuna E., Díaz Ó., Donner N., Giraldo J., Groeneveld G., Gülave B., Guydan D., Hijma H., Maldonado R., Renault P., Rinaudo C., Elaissaiss‐Schaap J., Spiros A., Stoeber S., Takkala P., Valkengoed D.W. van, Hasselt C. van & Lange E.C.M. de (2026), In silico prediction of novel effective combinational treatment of chronic pain in individual patients: a joint white paper of the H2020 QSPainRelief consortium, British Journal of Pharmacology : .
- Guo Y., Guo T., Hasselt J.G.C. van & Zwep L.B. (2026), Copulas for covariate simulation in pharmacometrics, CPT: Pharmacometrics & Systems Pharmacology 15(4): e70242.
- Sudarsono L.M., Wenker S.A.M., Liu X., Brink J., Berg D.J. van den, Hasselt J.G.C. & Märtson A.G. (2026), A novel hollow-fiber infection model (HFIM) for antiviral PK/PD studies of CMV infection, Antimicrobial Agents and Chemotherapy 70(8): 1-12 (e00381-26).
- Tandar S.T., Zwep L.B, Woudt S.H.S., Schoffelen A.F., Smits W.K., Aulin L.B.S., Liakopoulos A., Hasselt J.G.C., Cohen S.J.W.T., Melles D.C., Dijk K. van, Alzubaidy A., Scholing M., Kuil S.D., Blaauw G.J., Bijllaardt W., Kraan E.M., Haeseker M.B., Da Silva J.M., Jong E. de, Maraha B., Griethuysen A.J. van, Wintermans B.B., Trijp M.J.C.A. van, Muller A.E., Wong M., Ott A., Bathoorn E., Lokate M., Sinnige J., Melles D.C., Bank L., Sebens F.W., Renders N.H., Dorigo-Zetsma J.W., Bakker L.J., Ang W., Waar K., Beek M.T. van der, Leversteijn-van Hall M.A., Mens S.P. van, Schaftenaar E., Nabuurs-Franssen M.H., Maat I., Sturm P.D.J., Diederen B.M.W., Bode L.G.M., Ong D.S.Y., Rijn M. van, Dinant S., Reijer M. den, Dam D.W., Brauwer E.I.G.B., Bentvelsen R.G., Stohr J.J.J.M., Vlek A.L.M., Graaf M. de, Troelstra A., Gast K.B., Meer M.P. A., Vries J. de, Debast S.B., Altorf van der Kuil W., Bierman S.M., Greeff S.C. de, Groenendijk S.R.,Hertroys R., Kruithof L., Nauta I.M., Notermans D.W., Polman J., Reek W.J. van den, Schoffelen A.F., Velthuis F., Wielders C.C.H., Wit B.J. de & Zoetigheid R.E. (2026), Clinical prevalence of collateral sensitivity: a systematic exploration of multicentre antimicrobial surveillance data, The Lancet Microbe 7(4): 101274.
- Zandrajabi H., Os Wisse van, Smits W.K., Mortazavi S.A.,Tabatabaei-Yazdi F. & Hasselt J.G.C. van (2026), Collateral effects of antibiotic resistance in Campylobacter jejuni, FEMS Microbiology Letters 373: fnag089.
- Guo Y., Yin J., Aulin L.B.S., Ciofu O., Moser C., Upadhyay P.J., Høiby N., Wang H., Guo T. & Hasselt J.G.C. van (2026), Pharmacodynamic modeling of colistin and imipenem against in vitro Pseudomonas aeruginosa biofilms, Biofilm 12: 100387.
- Baars L.R., Gu M., Guo T. & Hasselt J.G.C. van (2026), Strain-dependent variability in pharmacodynamic interactions for phage-antibiotic combinations in Pseudomonas aeruginosa, International Journal of Antimicrobial Agents 67(10): 107895.
- Kok M., Hankemeier T. & Hasselt J.G.C. van (2025), Nutrient conditions affect antimicrobial pharmacodynamics in Pseudomonas aeruginosa, Microbiology Spectrum 13(1): e01409-24.
- Gülave B., Lesmana A., Lange E.C.M. de & Hasselt J.G.C. van (2025), Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?, Journal of Pharmacokinetics and Pharmacodynamics 52: 11.
- Gülave B., Maagdenberg H.W. van den, Boven L. van, Westen G.J.P. van, Lange E.C.M. de & Hasselt J.G.C. van (2025), Prediction of the extent of blood–brain barrier transport using machine learning and integration into the LeiCNS-PK3.0 model, Pharmaceutical Research 42: 281–289.
- Straub V.M., Barti B., Tandar S.T., Stevens A.F., Egmond N. van, Wel T. van der, Na Z., Rüegger J., Horst C. van der, Heitman L.H., Li Y., Stella N., Hasselt J.G.C. van, Katona I. & Stelt M. van der (2025), The endocannabinoid 2-arachidonoylglycerol is released and transported on demand via extracellular microvesicles, Proceedings of the National Academy of Sciences 122(8): e2421717122.
- Herzberg C. & Hasselt J.G.C. van (2025), Pharmacodynamics of interspecies interactions in polymicrobial infections, npj Biofilms and Microbiomes 11: 20.
- Heijden K.V. van der, Otto M.E., Schoones J.W., Esdonk M.J. van, Borghans L.G.J.M. van, Hasselt J.G.C. van, Gerven J.M.A. & Jacobs G. (2025), Clinical pharmacokinetics of N,N-dimethyltryptamine (DMT): a systematic review and post-hoc analysis, Clinical Pharmacokinetics 64(2): 215-227.
- Otto M.E., Heijden K.V. van der, Schoones J.W., Esdonk M.J. van, Borghans L.G.J.M., Jacobs G.E. & Hasselt J.G.C. van (2025), Clinical pharmacokinetics of psilocin after psilocybin administration: a systematic review and post-hoc analysis, Clinical Pharmacokinetics 64(1): 53-66.
- Otto M.E., Heijden K.V., Schoones J.W., Esdonk M.J. van, Borghans L.G.J.M., Jacobs G.E. & Hasselt J.G.C. van (2025), Correction: clinical pharmacokinetics of psilocin after psilocybin administration: a systematic review and post‑hoc analysis, Clinical Pharmacokinetics 64(3): 465-465.
- Bock M., Hasselt J.G.C. van, Fuursted K., Ihlemann N., Gill S., Christiansen U., Bruun N.E., Elming H., Povlsen J.A.., Køber L., Høfsten D.E., Fosbøl E.L., Pries-Heje M.M., Christensen J.J. Rosenvinge F.S., Pedersen C.T., Helweg-Larsen J., Tønder N., Iversen K., Bundgaard H. & Moser C. (2025), Target attainment of benzylpenicillin in patients with infective endocarditis, Clinical Microbiology and Infection 31(8): 1350-1355.
- Maagdenberg H.W. van den, Mol van Otterloo J. de, Hasselt J.G.C. de, Graaf P.H. van der & Westen G.J.P van (2025), Integrating pharmacokinetics and quantitative systems pharmacology approaches in generative drug design, Journal of Chemical Information and Modeling 65(10): 4783-4796.
- Budda D., Zhang Z., Hasselt J.G.C. van & Lange E.C.M. de (2025), Beta-endorphin is the key endogenous opioid influencing morphine µ-opioid receptor occupancy in rat hypothalamus: a binding kinetic model analysis, European Journal of Pharmaceutical Sciences 212: 107195.
- Kok M., Os W. van, Hankemeier T. & Hasselt J.G.C. van (2025), Prolonged anoxic exposure impacts antibiotic sensitivity profiles of Pseudomonas aeruginosa, FEMS Microbiology Letters 372: fnaf066.
- Alarcon Rios A.C., Zwep L.B., Vriesendorp B., Knibbe C.A.J., Ciofu O., Liakopoulos A., Aulin L.B.S., Rozen D.E. & Hasselt J.G.C. van (2025), Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth, Antimicrobial Agents and Chemotherapy 69(10): e00421-25.
- Guo Y., Yin J., Yonucu S., Knibbe C.A.J., Guo T. & Hasselt J.G.C van (2025), Spatial pharmacokinetic and pharmacodynamic modeling in airway mucus, Clinical Pharmacokinetics 64: 1869-1883.
- Sudarsono L., Puspitasari K., Liu X., Hasselt J. van & Märtson A. (2025), Antiviral dose response against CMV infection varies with the timing of treatment initiation, British Journal of Clinical Pharmacology 91(S1): 20-21.
- Liu X, Jasinga M., Sudarsono L.M., Hasselt J.G.C. van. & Märtson A.G. (2025), Mechanistic viral dynamic modelling of in vitro cytomegalovirus infection based on viral DNA and viral titre, British Journal of Clinical Pharmacology 91(S1): 20.
- Wenker S.A.M., Hasselt J.G.C. van., Moes D.J.A.R. & Märtson A. (2025), Target attainment of valganciclovir prophylaxis against cytomegalovirus, British Journal of Clinical Pharmacology 91(S1): 8-9.
- Beek H. van de, Välitalo P.A.J., Hasselt J.G.C van & Zwep L.B. (2025), Aggregate data modelling: a fast implementation for fitting pharmacometrics models to summary-level data in R, Journal of Pharmacokinetics and Pharmacodynamics 53(1): 3.
- Kok M., Zwep L.B., Jansen R.S., Hankemeier T. & Hasselt J.G.C. van (2025), Nutrients drive the antibiotic-specific evolution of resistance in Pseudomonas aeruginosa, Research in Microbiology 176(8): 1-9 (104323).
- Mehta K.M., Guo T. & Graaf P.H. van der Hasselt J.G.C. van (2024), Model‐based dose optimization framework for bedaquiline, pretomanid, and linezolid for the treatment of drug‐resistant tuberculosis, British Journal of Clinical Pharmacology 90(2): 463-474.
- Tandar S.T., Aulin L.B.S., Leemkuil E. M.J., Liakopoulos A. & Hasselt J.G.C. van (2024), Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations, Journal of Pharmacokinetics and Pharmacodynamics 51: 199-211.
- Zwep L.B., Guo T., Nagler T.W., Knibbe C.A.J., Meulman J.J. & Hasselt J.G.C. van (2024), Virtual patient simulation using copula modeling, Clinical Pharmacology & Therapeutics 115(4): 795-804.
- Higazy D., Pham A.D., Hasselt C. van, Høiby N, Jelsbak L., Moser C. & Ciofu O. (2024), In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection, The ISME Journal 18(1): wrae036.
- Mehta K.M., Balazki P., Graaf P.H. van der, Guo T. & Hasselt J.G.C. van (2024), Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 63: 657-668.
- Budda D., Gülave B., Hasselt J.G.C. van & Lange E.C.M. de (2024), Non‐linear blood–brain barrier transport and dosing strategies influence receptor occupancy ratios of morphine and its metabolites in pain matrix, British Journal of Pharmacology 181(20): 3856-3868.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2024), Corrigendum to “Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?” , European Journal of Pharmaceutical Sciences 196: 106736.
- Guo Y., Guo T., Knibbe C.A.J., Zwep L.B. & Hasselt J.G.C. van (2024), Generation of realistic virtual adult populations using a model-based copula approach, Journal of Pharmacokinetics and Pharmacodynamics 51: 735-746.
- Os W. van, Pham A.D., Eberl S., Minichmayr I.K., Hasselt J.G.C. van & Zeitlinger M. (2024), Integrative model-based comparison of target site-specific antimicrobial effects: a case study with ceftaroline and lefamulin, International Journal of Antimicrobial Agents 63(5): 107148.
- Herzberg C., Meegen E.N. van & Hasselt J.G.C. van (2024), Interplay of virulence factors shapes ecology and treatment outcomes in polymicrobial infections, Mathematical Biosciences 377: 109293.
- Hartog I. den, Zwep L.B., Meulman J.J., Hankemeier T., Garde E.M.W. van de & Hasselt J.G.C. van (2024), Longitudinal metabolite profiling of Streptococcus pneumoniae-associated community-acquired pneumonia, Metabolomics 20(2): 35.
- Yin A., Veerman G.D.M., Hasselt J.G.C. van, Steendam C.M.J., Dubbink H.J.,Guchelaar H.J., Friberg L.E., Dingemans A.M.C., Mathijssen R.H.J. & Moes D.J.A.R. (2024), Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib, CPT: Pharmacometrics & Systems Pharmacology 13(4): 612-623.
- Maagdenberg H.W. van den, Šícho Martin A.D.A., Luukkonen S., Schoenmaker L., Jespers M., Béquignon O.J.M., Gorostiola González M.G., Broek R.L. van den, Bernatavicius R., Hasselt J.G.C. van, Graaf P.H. van der & Westen G.J.P. van (2024), QSPRpred: a flexible open-source quantitative structure-property relationship modelling tool, Journal of Cheminformatics 16: 128.
- Os W. van, Nussbaumer-Pröll A., Pham A.D., Wijnant G.J., Ngougni Pokem P., Bambeke F. Van, Hasselt J.G.C. van & Zeitlinger M. (2024), Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections, Journal of Antimicrobial Chemotherapy 79(10): 2484-2492.
- Sanz-Codina M., Os W. van, Pham A.D., Jorda A., Wölfl-Duchek M., Bergmann F., Lackner E., Lier C., Hasselt J.G.C. van, Minichmayr I.K., Dorn C., Zeitlinger M. & Al Jalali V. (2024), Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers, Journal of Antimicrobial Chemotherapy 79(12): 3281-3288.
- Groesen E. van, Mons E., Kotsogianni A.I., Arts M., Tehrani K.H.M.E., Wade N., Lysenko V., Stel F.M., Zwerus J.T., De Benedetti S., Bakker A.T., Chakraborty P., Stelt M. van der, Scheffers D.-J., Gooskens J., Smits W.K., Holden K., Gilmour P., Willemse J.J., Hitchcock C.A., Hasselt J.G.C. van, Schneider T. & Martin N.I. (2024), Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity, Science Translational Medicine 16(759): eabo4736.
- Troisi C.I.C., Cojutti P.G., Rinaldi M.,Tonetti T., Siniscalchi A., Hasselt J.G.C. van, Viale P. & Pea F. (2024), Impact of continuous infusion meropenem PK/PD target attainment on C-reactive protein dynamics in critically ill patients with documented gram-negative hospital-acquired or ventilator-associated pneumonia, Clinical Pharmacokinetics 63(11): 1573-1583.
- Jong L.M. de, Kreeke A.M. van de, Ahmadi M., Swen J.J., Knibbe C.A.J., Hasselt J.G.C. van, Manson M.L. & Krekels E.H.J. (2024), Changes in plasma clearance of CYP450 probe drugs may not be specific for altered in vivo enzyme activity under (patho)physiological conditions : how to interpret findings of probe cocktail studies, Clinical Pharmacokinetics 63(11): 1585-1595.
- Maagdenberg H.W. van den, Sicho M., Araripe D.A., Luukkonen S., Schoenmaker L., Jespers M., Bequignon O.J.M., Gorostiola González M., Broek R.L. van den, Bernatavicius A., Hasselt J.G.C. van, Graaf P.H. van der & Westen G.J.P. van (2024), QSPRpred: a flexible open-source quantitative structure-property relationship modelling tool, Journal of Cheminformatics 16(1): 128.
- Koumans C.I.M., Tandar S.T., Liakopoulos A. & Hasselt J.G.C. van (2024), Interspecies interactions alter the antibiotic sensitivity of Pseudomonas aeruginosa, Microbiology Spectrum 12(12): e02012-24.
- Bock M., Theut A.M., Hasselt J.G.C. van, Wang H., Fuursted K., Høiby N., Lerche C.J., Ihlemann N., Gill S., Christiansen U., Nielsen H.L., Lemming L., Elming H., Povlsen J.A., Bruun N.E., Høfsten D., Fosbøl E.L., Køber L., Schultz M., Pries-Heje M.M., Kristensen J.H, Christensen J.J., Rosenvinge F.S., Pedersen C.T., Helweg-Larsen J., Tønder N., Iversen K., Bundgaard H. & Moser C. (2023), Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a POET substudy, Clinical Infectious Diseases 77(2): 242-251.
- Hartog I. den, Karu N., Zwep L.B., Voorn P.G., Garde E.M.W. van de, Hankemeier T. & Hasselt C.J.G. van (2023), Differential metabolic host response to pathogens associated with community-acquired pneumonia, Metabolism open 18: 100239.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2023), Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?, European Journal of Pharmaceutical Sciences 187: 106482.
- Fu Y., Snelder N., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Evaluation of a cardiovascular systems model for design and analysis of hemodynamic safety studies, Pharmaceutics 15(4): 1175.
- Mehta K.M., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 62(3): 519-532.
- Janssen J.M., Damoiseaux D., Hasselt J.G.C. van, Amant F.C.H., Calsteren K., Beijnen J.H., Huitema A.D.R. & Dorlo T.P.C. (2023), Semi-physiological enriched population pharmacokinetic modelling to predict the effects of pregnancy on the pharmacokinetics of cytotoxic drugs, Clinical Pharmacokinetics 62(8): 1157-1167.
- Bock M., Hasselt J.G.C. van, Schwartz F., Wang H., Høiby N., Fuursted K., Ihlemann N., Gill S., Christiansen U., Bruun N.E., Elming H., Povlsen J.A., Køber L., Høfsten D.E., Fosbøl E.L., Pries-Heje M.M., Christensen J.J., Rosenvinge F.S., Torp-Pedersen C., Helweg-Larsen J., Tønder N., Iversen K., Bundgaard H. & Moser C. (2023), Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis, Journal of Antimicrobial Chemotherapy 78(12): 2840–2848.
- Liu F., Aulin L.B.S. & Manson M.L. Krekels E.H.J. Hasselt J.G.C. van (2023), Unraveling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism, European Journal of Drug Metabolism and Pharmacokinetics 48: 623–631.
- Mehta K.M., Spaink H.P., Ottenhoff T.H.M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches, Trends in Pharmacological Sciences 43(4): 293-304.
- Liakopoulos A., Aulin L.B.S., Buffoni M., Fragkiskou E., Hasselt J.G.C. van & Rozen D.E. (2022), Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution, Proceedings of the National Academy of Sciences 119(18): e2121768119.
- Fu Y., Taghvafard H., Said M.M., Rossman E.I., Collins T.A., Billiald-Desquand S., Leishman D., Graaf P.H. van der, Hasselt J.G.C. van & Snelder N. (2022), A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables, CPT: Pharmacometrics and Systems Pharmacology 11(5): 640-652.
- Vinkenoog M., Steenhuis M., Brinke A. ten, Hasselt J.G.C. van: Janssen M.P., Leeuwen M. van, Swaneveld F.H., Vrielink H., Watering L. van de, Quee F., Hurk K. van den, Rispens T., Hogema B. & Schoot C.E. van der (2022), Associations between symptoms, donor characteristics and IgG antibody response in 2082 COVID-19 convalescent plasma donors, Frontiers in Immunology 13: 821721.
- Guo T., Abdulla A., Koch B.C.P., Hassel J.G.C. van, Endeman H., Schouten J.A., Elbers P.W.G., Brüggeman R.J.M. & Hest R.M. (2022), Pooled population pharmacokinetic analysis for exploring ciprofloxacin pharmacokinetic variability in intensive care patients, Clinical Pharmacokinetics 61(6): 869-879.
- Kok M., Maton L., Peet M.P. van der, Hankemeier T. & Hasselt J.G.C. van (2022), Unraveling antimicrobial resistance using metabolomics, Drug Discovery Today 27(6): 1774-1783.
- Aulin L.B.S., Kleijburg A., Moerland M. & Hasselt J.G.C. van (2022), Characterizing the kinetics of presepsin and associated inflammatory biomarkers in human endotoxemia, Inflammation Research 71(9): 999-1001.
- Liu F., Aulin L.B.S., Guo T., Krekels E.H.J., Moerland M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations, British Journal of Clinical Pharmacology 88(12): 5420-5427.
- Liu F., Aulin L.B.S., Kossen S.S.A., Cathalina J.E.J., Bremmer M., Foks A.C., Graaf P.H. van den Moerland M. & Hasselt J.G.C. van (2022), A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis, Journal of Pharmacokinetics and Pharmacodynamics 49(6): 645-655.
- Maas P., Hartog I. den, Kindt A.S.D., Boman S., Hankemeier T. & Hasselt J.G.C. van (2022), The Immunometabolic Atlas: a tool for design and interpretation of metabolomics studies in immunology, PLoS ONE 17(5): e0268408.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J.A.R. (2022), Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4206.
- Aulin L.B.S., Tandar S.T., Zijp T. van, Ballegooie E. van, Graaf P.H. van der, Saleh M.A.A.E.W., Välitalo P. & Hasselt J.G.C. van (2022), Physiologically based modelling framework for prediction of pulmonary pharmacokinetics of antimicrobial target site concentrations, Clinical Pharmacokinetics 61: 1735-1748.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J. (2022), Publisher correction: anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4879 (4879).
- Mehta K.M., Guo T., Wallis R.S., Graaf P.H. van der & Hasselt J.G.C. van (2022), Quantitative systems pharmacology modeling framework of autophagy in tuberculosis: application to adjunctive metformin host-directed therapy, Antimicrobial Agents and Chemotherapy 66(8): e0036622.
- Aulin L.B.S., De Paepe. P., Dhont E., Jaeger A. de, Vande Walle J., Vandenberghe W., McWhinney B.C., Ungerer J.P.J., Hasselt J.G.C. van & Cock P.A.J.G. de (2021), Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients, Clinical Pharmacokinetics 60: 353-363.
- Rahman R., Zatorski N., Hansen J., Xiong Y., Hasselt J.G.C. van, Sobie E.A., Birtwistle M.R., Azeloglu E.U., Iyengar R. & Schlessinger A. (2021), Protein structure-based gene expression signatures, Proceedings of the National Academy of Sciences 118(19): e2014866118.
- Keij F.M., Koch B.E.V., Lozano Vigario F., Simons S.H.P., Hasselt J.G.C. van, Knibbe C.A.J., Spaink H.P., Reiss I.K.M. & Krekels E.H.J. (2021), Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis, Journal of Clinical and Translational Science 5(1): e140.
- Hartog I. den, Zwep L.B., Vestjens S.M.T., Harms A.C., Voorn G.P., Lange D.W. de, Bos W.J.W., Hankemeier T., Garde E.M.W. & Hasselt J.G.C. van (2021), Metabolomic profiling of microbial disease etiology in community-acquired pneumonia, PLoS ONE 16(6): e0252378.
- Poppe M., Clodi C., Schriefl C., Mueller M., Sunder-Plaßmann R., Reiter B., Rechenmacher M., Os W. van., Hasselt J.G.C., Holzer M., Herkner H., Schwameis M., Jilma B., Schoergenhofer C. & Weiser C. (2021), Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - a probe drug of CYP2C19 metabolism, Biomedicine & Pharmacotherapy 146: 112573.
- Zwep L.B., Haakman Y., Duisters K.L.W., Meulman J.J., Liakopoulos A. & Hasselt J.G.C. van (2021), Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data, JAC-Antimicrobial Resistance 3(4): dlab175.
- Fu Y., Snelder N., Graaf P.H. van der & Hasselt J.G.C. van (2020), Hemodynamic simulator: a shiny web application for predicting drug effect on hemodynamics, Journal of Pharmacological and Toxicological Methods 105: 23.
- Fu Y., Snelder N., Taghvafard H., Graaf P.H. van der & Hasselt J.G.C. van (2020), Hemodynamic systems model to characterize cardiovascular drug effects, Journal of Pharmacological and Toxicological Methods 105: 23.
- Hasselt J.G.C. van, Rahman R., Hansen J., Stern A., Shim J.V., Xiong Y., Pickard A., Jayaraman G., Hu B., Mahajan M., Gallo J.M., Goldfarb J., Sobie E.A., Birtwistle M.R., Schlessinger A., Azeloglu E.U. & Iyengar R. (2020), Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity, Nature Communications 11: 4809.
- Guo T.J., Hest R.M. van, Zwep L.B., Roggeveen L.F., Fleuren L.M., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Elbers P.W.G. & Hasselt J.G.C. van (2020), Optimizing predictive performance of bayesian forecasting for vancomycin concentration in intensive care patients, Pharmaceutical Research 37: 171.
- Guo T.J., Hest R.M. van, Fleuren L.M., Roggeveen L.F., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Hasselt J.G.C. van & Elbers P.W.G. (2020), Why we should sample sparsely and aim for a higher target: lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients, British Journal of Clinical Pharmacology 87(3): 1234-1242.
- Yu H., Janssen J.M., Sawicki E. Hasselt J.G.C. van, Weger V.A. de, Nuijen B., Schellens J.H.M., Beijnen J.H. & Huitema A.D.R. (2020), A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development, The Journal of Clinical Pharmacology 60(3): 340-350.
- Centanni M., Moes D.J.A.R., Trocóniz I.F., Ciccolini J. & Hasselt J.G.C. van (2019), Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors, Clinical Pharmacokinetics 58(7): 835-857.
- Hasselt J.G.C. van & Iyengar R. (2019), Systems Pharmacology: Defining the Interactions of Drug Combinations, Annual Review of Pharmacology and Toxicology 59: 21-40.
- Calizo R.C., Bhattacharya S., Hasselt J.G.C. van, Wei C., Wong J.S., Wiener R.J., Ge X., Wong N.J., Lee J.J., Cuttitta C.M., Jayaraman G., Au V.H., Janssen W., Liu T., Li H., Salem F., Jaimes E.A., Murphy B., Campbell K.N. & Azelogu E.U. (2019), Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity, Nature Communications 10: 2061.
- Yin A., Yamada A., Stam W.B., Hasselt J.G.C. van & Graaf P.H. van der (2018), Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction, British Journal of Pharmacology 175(16): 3394-3406.
- Illamola S.M., Sherwin C.M. & Hasselt J.G.C. van (2018), Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses, Clinical Pharmacokinetics 57(10): 1217-1228.
- Vries Schultink A.H.M. de, Boekhout A.H., Gietema J.A., Burylo A.M., Dorlo T.P.C., Hasselt J.G.C. van, Schellens J.H.M. & Huitema A.D.R. (2018), Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens, Journal of Pharmacokinetics and Pharmacodynamics 45(3): 431-442.
- Aulin L.B.S., Valitalo P.A., Rizk M.L., Visser S.A.G., Rao G., Graaf P.H. van der & Hasselt J.G.C. van (2018), Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans, Pharmaceutical Research 35(2): 26.
- Ramamoorthy A., Sadler B.M., Hasselt J.G.C. van, Elassaiss J., Kasichayanula S, Edwards A.Y., Graaf P.H. van der, Zhang L & Wagner J.A. (2018), Crowdsourced Asparagus Urinary Odor Population Kinetics, CPT: Pharmacometrics and Systems Pharmacology 7(1): 34-41.
- Saleh M.A.A.E.W., Garde E.M.W. van de & Hasselt J.G.C. van (2018), Host-response biomarkers for the diagnosis of bacterial respiratory tract infections, Clinical Chemistry and Laboratory Medicine 57(4): 442-451.
- Yamamoto Y., Välitalo P.A., Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Kokki H., Kokki M., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2018), Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach, European Journal of Pharmaceutical Sciences 112: 168-179.
- Yamamoto Y., Välitalo P.A., Berg D.J. van den, Hartman R.J., Brink W. van den, Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Bakshi S.D., Aranzana-Climent V., Marchand S., Dahyot-Fizelier C., Couet W., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations, Pharmaceutical Research 34(2): 333–351.
- Nguyen T.H.T., Mouksassi M.S., Holford N., Al-Huniti N., Freedman I., Hooker A.C., John J., Karlsson M.O., Mould D.R., Pérez Ruixo J.J., Plan E.L., Savic R., Hasselt J.G.C. van, Weber B., Zhou C., Comets E. & Mentré F. (2017), Model evaluation of continuous data pharmacometric models: Metrics and graphics, CPT: Pharmacometrics and Systems Pharmacology 6(2): 87-109.
- Yamamoto Y., Valitalo P.A.J., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Berg D.J. van den, Hartman R.J., Wong Y.C., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model, CPT: Pharmacometrics and Systems Pharmacology 6(11): 765–777.
- Kohler I., Hankemeier T., Graaf P.H. van der, Knibbe C.A.J. & Hasselt J.G.C. van (2017), Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine, European Journal of Pharmaceutical Sciences 109: S15-S21.
- Goulooze S.C., Krekels E.H.J., Dijk M. van, Tibboel D., Graaf P.H. van der, Hankemeier T., Knibbe C.A.J. & Hasselt J.G.C. van (2017), Towards personalized treatment of pain using a quantitative systems pharmacology approach, European Journal of Pharmaceutical Sciences 109: S32-S38.
- Krekels E.H.J., Hasselt J.G.C. van, Anker J.N. van den, Allegaert K., Tibboel D. & Knibbe C.A.J. (2017), Evidence-based drug treatment for special patient populations through model-based approaches, European Journal of Pharmaceutical Sciences 109(Supplement): S22-S26.
- Hasselt J.G. van, Rizk M.L., Lala M., Chavez-Eng C., Visser S.A., Kerbusch T., Danhof M., Rao G. & Graaf P.H. van der (2016), Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid, British Journal of Clinical Pharmacology 81: 1113–1123.
- Jacobs B.A., Deenen M.J, Pluim D, Hasselt J.G.C. van, Krähenbühl M.D., Geel R.M van, Vries N. de, Rosing H., Meulendijks D., Burylo A.M., Cats A., Beijnen J.H., Huitema A.D. & Schellens J.H. (2016), Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers, British Journal of Clinical Pharmacology 82(3): 706-716.
- Meulensdijks D., Hasselt J.G.C. van, Huitema A.D.R., Tinteren H. van, Deenen M.J., Beijnen J.H., Cats A. & Schellens J.H.M. (2016), Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care, European Journal of Cancer 2016(54): 120-130.
- Illamola S.M., Colom H. & Hasselt J.G. van (2016), Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies, British Journal of Clinical Pharmacology 82(3): 793-805.
- Valitalo P.A.J., Griffioen K., Rizk M., Visser S., Danhof M., Rao M., Graaf P. & Hasselt J.G.C. van (2016), Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid, Pharmaceutical Research 33(4): 856-867.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 386--395.
- Hasselt J.C. & Graaf P.H. (2015), Towards integrative systems pharmacology models in oncology drug development, Drug Discovery Today: Technologies 15: 1--8.
- Frederix G., Severens J., Hövels A., Hasselt J., Hooiveld M., Neven P., Raaijmakers J. & Schellens J. (2015), Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium, European Journal of Cancer Care 24(3): 340--354.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 374--385.
- Yu H., Steeghs N., Kloth J.S.L., Wit D., Hasselt J.G.C. van, Erp N.P., Beijnen J.H., Schellens J.H.M., Mathijssen R.H.J. & Huitema A.D.R. (2015), Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662, British Journal of Clinical Pharmacology 79(5): 809--819.
- Hasselt J.G.C. van, Allegaert K., Calsteren K. van, Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2014), Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy, BioMed Research International 2014(Article ID 897216): 1-9DO - 10.1155/2014/897216.
- Hasselt J.G.C. van, Calsteren K., Heyns L., Han S., Mhallem Gziri M., Schellens J.H.M., Beijnen J.H., Huitema A.D.R & Amant F. (2014), Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel, Annals of Oncology 25(10): 2059--2065.
- Hasselt J.G.C. van, Eijkelenburg N.KA., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2014), Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation, Pediatric Blood & Cancer 61(12): 2223--2229.
- Hasselt J.G.C. van, Schellens J.H.M., Beijnen J.H. & Huitema A.D.R. (2014), Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error, Investigational New Drugs 32(5): 913--927.
- Klumpers L.E., Roy C., Ferron G., Turpault S., Poitiers F., Pinquier J., Hasselt J.G.C. van, Zuurman L., Erwich F.A.S. & Gerven J.M.A. van (2013), Surinabant, a selective CB(1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans, British Journal of Clinical Pharmacology 76(1): 65-77.
- Hasselt J.G.C. van, Eijkelenburg N.K.A. van, Huitema A.D.R., Schellens J.H.M. & Schouten-van Meeteren A.Y.N. (2013), Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate, Antimicrobial Agents and Chemotherapy 57(6): 2878-81.
- Hasselt J.G.C. van, Eijkelenburg N.K.A. van, Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2013), Optimizing drug development of anti-cancer drugs in children using modelling and simulation, British Journal of Clinical Pharmacology 76(1): 30-47.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2013), Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia, British Journal of Clinical Pharmacology 76(6): 2878-81.
- Frederix G.W.J., Hasselt J.G.C. van, Schellens J.H.M., Hövels A.M., Raaijmakers J.A.M., Huitema A.D.R. & Severens J.L. (2013), The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance, Pharmacoeconomics : .
- Frederix G.W.J., Hasselt J.G.C. van, Severens J.L., Hovels A.M., Huitema A.D.R., Raaijmakers J.A.M. & Schellens J.H.M. (2013), Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R, Medical Decision Making 33(6): 780-792.
- Frederix G.W.J., Severens J.L., Hövels A.M., Hasselt J.G.C. van, Raaijmakers J.A.M. & Schellens J.H.M. (2013), Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer, Breast Cancer Research and Treatment 139(2): 489-495.
- Klumpers L.E., Beumer T.L., Hasselt J.G.C. van, Lipplaa A., Karger L.B., Kleinloog D., Freijer J.I., Kam M.L. de & Gerven J.M.A. van (2012), Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects, British Journal of Clinical Pharmacology 74(1): 42-53.
- Mallaysamy S., Johnson M.G., Rao P.G.M., Rajakannan T., Bathala L., Arumugam K., Hasselt J.G.C. van & Ramakrishna D. (2012), Population pharmacokinetics of lamotrigine in Indian epileptic patients, European Journal of Clinical Pharmacology 69(1): 43-52.
- Broek M.P.H. van den, Groenendaal F., Toet M.C., Straaten H.L.M. van, Hasselt J.G.C. van, Huitema A.D.R., Vries L.S. de, Egberts A.C.G. & Rademaker C.M.A. (2012), Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia : a thermopharmacological approach, Clinical Pharmacokinetics 51(10): 671-679.
- Hasselt J.G.C. van, Green B. & Morrish G.A. (2012), Leveraging Physiological Data from Literature into a Pharmacokinetic Model to Support Informative Clinical Study Design in Pregnant Women, 29(6): 1609-1617.
- Hasselt J.G.C. van, Schellens J.H.M., Mac Gillavry M.R., Beijnen J.H. & Huitema A.D.R. (2012), Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab, 29(12): 3499-3511.
- Hasselt J.G.C. van, Heuvel M.M. van den, Schellens J.H.M., Beijnen J.H., Brandsma D. & Huitema A.D.R. (2012), Severe Cannabinoid Intoxication in a Patient with Non Small Cell Lung Cancer, Journal of palliative care 28(1): 60-61.
- Hasselt J.G.C. van, Andrew M.A., Hebert M.F., Tarning J., Vicini P. & Mattison D.R. (2012), The Status of Pharmacometrics in Pregnancy: Highlights from the 3(rd) American Conference on Pharmacometrics, British Journal of Clinical Pharmacology 74(6): 932-939.
- Broek M.P.H. van den, Huitema A.D.R., Hasselt J.G.C. van, Groenendaal F., Toet M.C., Egberts T.C.G., Vries L.S. de & Rademaker C.M.A. (2011), Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures, Clinical Pharmacokinetics 50(7): 461-469.
- Hasselt J.G.C. van, Boekhout A.H., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2011), Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity, Clinical Pharmacology & Therapeutics 90(1): 126-132.
- Krekels E.H.J., Hasselt J.G.C. van, Tibboel D., Danhof M. & Knibbe C.A.J. (2011), Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models, Pharmaceutical Research 28(4): 797-811.
- Liem-Moolenaar M., Boer P. de, Timmers M., Schoemaker R.C., Hasselt J.G.C. van, Schmidt S. & Gerven J.M.A. van (2011), Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects, British Journal of Clinical Pharmacology 71(6): 886-898.
- Dumont G.J.H., Hasselt J.G.C. van, Kam M. de, Gerven J.M.A. van, Touw D.J., Buitelaar J.K. & Verkes R.J. (2011), Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers, Journal of Psychopharmacology 25(4): 478-489.
- Lo Y.L., Hasselt J.G.C. van, Heng S.C., Lim C.T., Lee T.C. & Charles B.G. (2010), Population pharmacokinetics of vancomycin in premature malaysian neonates: identification of predictors for dosing determination, Antimicrobial Agents and Chemotherapy 54(6): 2626-2632.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U.R., Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology & Therapeutics 86(1): 44-48.
- Dumont G.J.H., Kramers C., Sweep F.C., Touw D.J., Hasselt J.G.C. van, Kam M.L. de, Gerven J.M.A. van, Buitelaar J.K. & Verkes R.J. (2009), Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans, Clinical Pharmacology & Therapeutics 86(2): 160-166.
- Consultancy
- Organisatie wetenschappelijke bijeenkomsten
- PhD supervision and Scientific Advisor
- Penningmeester